NTT Takes New Steps to Grow Its Global Business, Drive Innovation Going Forward
Nippon Telegraph and Telephone Corporation (NTT Corporation) (TOKYO: 9432) is pleased to announce several initiatives to be implemented soon. These steps will help us become more competitive and profitable, and create new ways of serving clients and society through our global business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180806005721/en/
* NTT DATA will continue to collaborate with other companies in the Group while retaining its present management structure, status as a listed company, management autonomy and brand. Please note: Other subsidiaries such as NTT Docomo, NTT EAST and NTT WEST are not described in this organisational chart. (Graphic: Business Wire)
1. Why we need to transform
Our operating companies – NTT Communications, Dimension Data, NTT DATA,
and NTT Security –have continued to evolve and grow their respective
capabilities. NTT Group has also been driving collaboration across these
operating companies with great success. To date, these activities have
resulted in collective revenue outside of Japan of U.S. $20 billion.
The global market is changing fast. We’ve seen rapid progress in technology innovation; disruption caused by new business models, and the aggressive expansion of innovative competitors. These factors have led to clients’ increasing demand for digital transformation. We believe it’s an opportunity for us to create new value and increase our presence in the global market.
2. What we plan to do
(1) Establish a new holding company focused on global business
We’re establishing a new global holding company under NTT Corporation by the third quarter of the fiscal year ending March 31, 2019. This entity will be called NTT, Inc., and Jun Sawada, current CEO of NTT Corporation, will also serve as its CEO. Estimated operating revenue of NTT, Inc. is approximately U.S. $38 billion with U.S. $20 billion already coming from outside Japan (consolidated figures, based on the fiscal year ending March 31, 2018).
By the third quarter of the fiscal year ending March 31, 2019, NTT Communications, Dimension Data, NTT DATA, NTT Security, and NTTi3 will be transferred to NTT, Inc. and will align together under its new leadership.
While making NTT Group more competitive and profitable, our global governance will also benefit from embracing and integrating our people’s diverse talents, skills, and management experience in global markets. The new structure will leverage their expertise to its maximum potential.
In addition, by the second quarter of the fiscal year ending March 31, 2020, we’ll consider integrating these businesses – except NTT DATA – into two new businesses. One will look after our global business; the other will cater for our domestic business in Japan.
NTT DATA will continue to collaborate with other companies in the Group while retaining its present management structure, status as a listed company, management autonomy and brand.
(2) Expanding our global R&D capability
Further steps will include creating a new global innovation fund: NTT Venture Capital, L.P. (a limited partnership), which will help us evolve our global innovation. With this new fund, we’ll activate investment in high-growth areas such as digital technology.
We’ll also intensify our R&D activities in global markets by using a global network of experts from advanced academic research institutions and venture-capital communities around the world.
About the global holding company
(1)Company name: NTT, Inc.
(2)Headquarters: Tokyo, Japan
(3)CEO: Jun Sawada, current president and CEO of NTT Corporation, will also serve as CEO of NTT, Inc.
(4)Main business activities: Governance and strategic planning of the global business of NTT Group
(5)Capital: JPY600 billion (After the transfer of every subsidiary is completed)
(6)Share holder: Wholly owned by NTT Corporation
(7)Number of employees: Approximately 163,000 employees (consolidated figure)
(8)Schedule: To be established by the third quarter of the fiscal year ending March 31, 2019
About the global innovation fund
(1)Fund name: NTT Venture Capital, L.P.
(2)Fund size: Up to U.S. $500 million
(3)Main investment area: High-growth areas such as digital technology.
Public Relations Office
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an